Geneos Wealth Management’s CareDx CDNA Stock Holding History

Geneos Wealth Management’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-47	Closed	-$3K	–	2886
2021 Q1	$3K	Buy	+47	New	+$3.65K	﹤0.01%	2782
2019 Q1	–	Sell	-750	Closed	-$17K	–	2412
2018 Q4	$17K	Hold	750	–	–	﹤0.01%	1561
2018 Q3	$21K	Sell	750 -1,050	-58%	-$19.6K	﹤0.01%	1545
2018 Q2	$22K	Buy	+1,800	New	+$20.6K	﹤0.01%	1399

Other funds holding CDNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Geneos Wealth Management's CDNA Position: Q2 2021 in Review

Geneos Wealth Management sold out of CareDx (CDNA) in Q2 2021, closing a stake of 47 shares — an estimated $3K sold.

Geneos Wealth Management first reported a position in CDNA in Q2 2018 and held it in 4 quarters. The position peaked at $22K in Q2 2018. 254 funds tracked by Wall St. Rank hold CDNA as of Q2 2021.

Geneos Wealth Management reported no remaining CareDx position as of Q2 2021 after selling out during the quarter.
Geneos Wealth Management sold 47 CareDx shares in Q2 2021, an estimated $3K.
Geneos Wealth Management first reported a position in CareDx in Q2 2018 and held it in 4 quarters.
Geneos Wealth Management's CareDx position peaked at $22K in Q2 2018.
254 funds tracked by Wall St. Rank held CareDx as of Q2 2021.

Based on Geneos Wealth Management's 13F filing for Q2 2021, filed 8 Jul 2021.